KCT0002927已完成未知
A 12 week, multi-center, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of NVP-1702 on improving liver function
VP Healthcare0 个研究点目标入组 90 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 75(Year)（—）
- 性别
- All
入选标准
- •1) Male and female subject aged between 19 years and 75 years
- •2) Subjects with AST(Aspartate Aminotransferase)(GOT) level 45~120U/L or ALT(Alanine Aminotransferase)(GPT) level 45~120U/L
- •3) Subjects with a body mass index (BMI) of 23 kg / m^2 or more
- •4) Subjects who agree to participate in the study and sign the informed consent form
排除标准
- •1) Subject with liver cirrhosis or hepatoma on ultrasonography
- •2) Subject with ?-GTP(Gamma Glutamyl Transpeptidase) > 210U/L
- •3) During the past one month in the drinking lifestyle survey, more than the average male in a week 14-unit, female in a week 7-unit
- •4) Subject with Alkaline Phosphatase(ALP) = 390U/L or Platelet = 10^5/ul or AFP(a-fetoprotein) > 20 ng/mL
- •5) Subject diagnosed with viral hepatitis
- •6) Subject with HBs Ag(Hepatitis C Virus Antibodies) or HCV Ab(Hepatitis C Virus Antibodies) positive in screening test
- •7) Subject with Albumin = 3.5g/dl or Total Bilirubin = 3 mg/dl
- •8) Subject with Creatinine = 2.4mg/dL
- •9) Subject who TSH(Thyroid Stimulating Hormone) = 0.1uU/ml and = 10uU/ml
- •10) Subject who taking a drug influence of liver function (INH(isoniazid), valproic acid, tetracycline, allopurinol, phenytoin, phenelzine, sertraline, naproxen, diclofenac, the potential to cause liver toxicy.)within 4 weeks
- •11) Subject taking cholagogues, cholelitholytics, hepatic Protectors, antidotes, detoxifying agents and drugs used in substance dependence within 4 weeks
- •12) Subject taking the asian herb, Vit(vitamin). E supplement, Liver function improvement and related health supplements within 2 weeks
- •13) Subject taking the adrenal cortex hormones or sex hormones to the start of the study within 4 weeks
- •14) Subjects who cannot take a Investigational Product because of heartburn, indigestion and severe gastrointestinal symptoms
- •15) Pregnant or get the pregnant person during a clinical trial
- •16) planning to participate in other clinical trial during the clinical trial
- •17) Who was participated in the clinical trials to the start of the study within a month
- •18) Investigator this clinical trial the person who are deemed inappropriate
研究者
相似试验
尚未招募
不适用
A 12 week, multi-center, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of opuntia ficus-indica extract on improving liver funtion.KCT0000867Elcomscience80
招募中
不适用
Efficacy and safety study of WSY-SKCT0003761Kyung Hee University Hosipital at Gangdong80
招募中
不适用
A 12 week, multi-center, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of Citrus aurantium extract on improving liver functioDiseases of the digestive systemKCT0001869utraPharmTech100
招募中
不适用
clinical trial for the evaluation of the efficacy and safety of BRB-F on improving liver functioDiseases of the digestive systemKCT0002143STR Biotech80
招募中
不适用
A 12 week, multi-center, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of NVP-1702 on improving alcoholic liver functioDiseases of the digestive systemKCT0002928VP Healthcare100